Justice
Forum Fanatic
Topics: 106
Posts: 2,105
|
Colleagues,
we know that about 15% of AML are positive for Philadelphia chromosome [t(9:22). However, most of our sources do not indicate if Gleevec could be used to treat these Pts. So far we know that Gleevec is used to treat CML.
So, here is an info to demonstrate that Gleevec can be used to treat Phil-Chrom-positive AML Pts. Whether we see this kind of Q on the exam, I do not know.
--
Haematologica. 2004 May 1;89(5):ECR15. Print 2004 May. Related Articles, Links
Click here to read
Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
Jentsch-Ullrich K, Pelz AF, Braun H, Koenigsmann M, Mohren M, Wieacker P, Franke A.
University Hospital Magdeburg, Division of Hematology/Oncology, Leipziger Str.44, 39120 Magdeburg, Germany. Kathleen.Jentsch-Ullrich@Medizin.Uni-Magdeburg.de
Philadelphia-chromosome (Ph)-positive acute myeloid leukemia (AML) is rare and prognosis is poor with a median survival of six to seven months only. We report on a patient with Ph-positive AML (FAB M2, major BCR/ABL1 mRNA transcript, b2a2), who is in sustained complete cytogenetic and molecular remission for 15 months. Cytarabine-based chemotherapy was discontinued after two courses due to infectious complications. Since the b2a2 transcript was still detectable, imatinib was started with quantitative RT-PCR monitoring. This result is promising and worth further evaluation to establish the role of imatinib in patients with Ph-positive AML.
___________________
Don't live in a town where there are no doctors
|
| sprint123
Forum Guru
Topics: 129
Posts: 870
|
Thanks justice..Is Gleevec is used for ph-chr negative(5%) CML patients???
|
| Justice
Forum Fanatic
Topics: 106
Posts: 2,105
|
Gleevec had been tried in these Pts with no cytogenetic/clinical success... 
___________________
Don't live in a town where there are no doctors
|
| doyoudig
Forum Guru
Topics: 144
Posts: 613
|
thx for the info!!
|
|
| |
| | | | |
